Key result
Rivaroxaban discontinuation in VTE patients is followed by ~4% symptomatic recurrence.
Why the study?
Rivaroxaban is used as first-line treatment for VTE, but the frequency of its discontinuation and subsequent clinical outcomes remain unclear.
What is the frequency of rivaroxaban discontinuation and subsequent clinical outcomes in Japanese patients with venous thromboembolism?
Cohort (n=579)
Open-label
Yes
What is the frequency of rivaroxaban discontinuation and subsequent clinical outcomes in Japanese patients with venous thromboembolism?
Answers are grounded in this paper and cite their sources.
Observed recurrence and bleeding rates after rivaroxaban discontinuation support individualized decisions; leaves optimal duration open in Japanese VTE patients.
Background Rivaroxaban, a direct oral anticoagulant, is used as first-line treatment to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). However, the frequency of rivaroxaban discontinuation and the subsequent clinical outcomes remain unclear. Methods and Results The study was a subanalysis of the prospective, multicenter, observational J’xactly study, conducted in Japan, and included patients who underwent anticoagulant discontinuation without major bleeding and recurrent VTE. The modified intention-to-treat population (n=1,016) included 579 patients (57%) who underwent anticoagulant discontinuation during a mean follow-up period of 20.2 months (mean [±SD] anticoagulation period 6.9±6.2 months). Patients were divided into 3 groups: those with active cancer, those without active cancer and a transient risk factor for VTE, and those without active cancer or a transient risk factor and/or with previous VTE (unprovoked group). After discontinuation, VTE recurrence occurred in 4.1% of patients, with an annual incidence of 4.6%/year and an increased tendency in the unprovoked group; major bleeding occurred in 8 patients (1.4%; annual incidence 1.1%/year), of whom half were in the cancer group. Conclusions This analysis of a real-world observational study provides data on VTE recurrence after rivaroxaban discontinuation, which will facilitate anticoagulant discontinuation according to individual risk-benefit considerations.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2022) conducted a cohort in Venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) (n=579). Rivaroxaban discontinuation (compared across unprovoked, transient risk factor, and active cancer VTE subgroups) vs. Transient risk factor VTE group was evaluated on Recurrence or aggravation of symptomatic venous thromboembolism after rivaroxaban discontinuation (p=0.333). Rivaroxaban discontinuation in 57% of VTE patients was followed by symptomatic VTE recurrence in 4.1% and major bleeding in 1.4%.
Synapse has enriched 10 related papers. Consider them for comparative context: